Sarah L. Bliese, Ph.D. is an analytical chemist within the Medicines for All Institute where she generates and implements analytical methods to support process development for the Institute’s various projects. Previously she worked on the development of paper-based screening devices for monitoring pharmaceuticals during post-market surveillance studies in low- and middle-income countries. Sarah holds a B.S. in biology and B.S. in chemistry from Hamline University in St. Paul, MN and a Ph.D. in analytical chemistry from the University of Notre Dame.
Marek Buchman Ph.D. recently joined Medicines for All Institute as a Senior Research Scientist. Originally from Slovakia, Dr. Buchman obtained his MChem degree from the University of Oxford followed by his PhD studies with Prof. K.C. Nicolaou at Rice University in Houston, TX in the field of total synthesis of complex biologically active natural products such as novel anticancer agents and antibiotics. Before joining M4All, he was a post-doctoral research fellow at the pharmaceutical giant AbbVie in North Chicago, where he worked on the development of new methodologies for the synthesis of pharmaceutically relevant scaffolds.
Justina Burns, Ph.D. generates analytical chemistry methods to support process development at the Medicines for All Institute. Previously she worked in contract research supporting a variety of projects which included sample preparation/analysis, report writing and training. Additionally, Justina worked in the Mass Spectrometry Center at the University of South Carolina focusing on ICP-MS. She holds a B.S. in chemistry from University of Pittsburgh, Johnstown and a Ph.D. in analytical environmental chemistry from the University of South Carolina.
Flavio Cardoso, Ph.D., is a research scientist at Medicines for All Institute working on process development of APIs and/or key building blocks. Prior to joining M4ALL, he worked at Libbs Pharmaceuticals as R&D Coordinator where he gained experience in the development of synthetic processes for the manufacture of generic APIs. He holds a Ph.D. in organic chemistry from the University of Florida, where he designed and applied StackPhos, a new chiral biaryl heterocyclic ligand for enantioselective catalysis. Dr. Cardoso obtained his B.S. at UNICAMP (Brazil), where he applied palladium catalyzed cross-coupling reactions for the synthesis of biologically active compounds.
Daniel W. Cook, PhD is an analytical chemist within the Medicines for All Institute where he utilizes his expertise in separation sciences and chemometrics to develop and implement analytical methods to support the Institute’s various projects. He holds a B.S in chemistry from Randolph-Macon College in Ashland, VA and a Ph.D. in chemistry from VCU. Prior to his current role at M4ALL, he held a postdoctoral fellowship at VCU in the Chemical and Life Science Engineering department working on both the Pharmacy on Demand project under Dr. Thomas Roper and M4ALL under Dr. Frank Gupton. He transitioned into his current role in early 2019.
Ryan Nelson, Ph.D., is a research scientist who joined the M4ALL team in the summer of 2019. His contributions to the group range from on-paper route development to benchtop route scouting and scale up. Previously, Ryan was a faculty member at Bowdoin and Bates Colleges in Maine, where he taught a variety of chemistry courses and contributed to several collaborative research projects. Ryan received his bachelor’s degree from Gustavus Adolphus College and his Ph.D. from the University of Wisconsin-Madison. He also held post-doctoral research positions at Argonne National Laboratory and University of California, Santa Barbara.
Tai holds BSc and MPhil degrees from the University of Hong Kong, and PhD in organic chemistry from Imperial College London on a British Commonwealth scholarship. He completed his postdoctoral training in organic synthesis at the Scripps Research Institute. Tai worked as a process chemist in the pharmaceutical industry for 18 years (DuPont Pharmaceutical, BMS, and Incyte). He was senior director of process chemistry at Incyte prior to joining the Clinton Health Access Initiative as scientific director in 2015.